Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 1;58(27):9234-9238.
doi: 10.1002/anie.201901589. Epub 2019 May 27.

Synthetic Lugdunin Analogues Reveal Essential Structural Motifs for Antimicrobial Action and Proton Translocation Capability

Affiliations

Synthetic Lugdunin Analogues Reveal Essential Structural Motifs for Antimicrobial Action and Proton Translocation Capability

Nadine A Schilling et al. Angew Chem Int Ed Engl. .

Abstract

Lugdunin, a novel thiazolidine cyclopeptide, exhibits micromolar activity against methicillin-resistant Staphylococcus aureus (MRSA). For structure-activity relationship (SAR) studies, synthetic analogues obtained from alanine and stereo scanning as well as peptides with modified thiazolidine rings were tested for antimicrobial activity. The thiazolidine ring and the alternating d- and l-amino acid backbone are essential. Notably, the non-natural enantiomer displays equal activity, thus indicating the absence of a chiral target. The antibacterial activity strongly correlates with dissipation of the membrane potential in S. aureus. Lugdunin equalizes pH gradients in artificial membrane vesicles, thereby maintaining membrane integrity, which demonstrates that proton translocation is the mode of action (MoA). The incorporation of extra tryptophan or propargyl moieties further expands the diversity of this class of thiazolidine cyclopeptides.

Keywords: aldehyde peptide synthesis; methicillin-resistant Staphylococcus aureus; proton translocation; synthetic membrane vesicles; thiazolidine antibiotics.

PubMed Disclaimer

Conflict of interest statement

Eberhard Karls University Tübingen holds a patent (EP3072899B1) covering the compound lugdunin, derivatives thereof, and the bacterial infection prevention by lugdunin producing bacteria. The patent has also been filed in the USA (US2018/0155397A1).

Figures

Scheme 1
Scheme 1
Solid‐phase aldehyde peptide synthesis of 1.
Figure 1
Figure 1
Structure of lugdunin (1) and analogues 914.
Figure 2
Figure 2
Exemplified derivatives of 1. 4 is an inactive alanine analogue. The enantiomer 22 shows identical activity as 1. 23 and 24 are specially designed analogues of 1 with twofold and equal activity, respectively.
Figure 3
Figure 3
Effect of 1, 11, 22, and 3 on the S. aureus NCTC8325 membrane potential after 30 (black bars) and 60 minutes (gray bars) of treatment. The protonophore CCCP (5 μm) was used as a positive and DMSO as a negative control. Error bars represent the standard deviation (SD) of two biological replicates including two technical replicates each.
Figure 4
Figure 4
Complementary experiments excluding large pores or lesions. A) Fluorescence microscopy of S. aureus treated with pore‐forming nisin (1–2 × MIC) or 1 (10 × MIC). Scale bars: 1 μm. B) Time course of normalized CF leakage from POPC vesicles, induced by 25 and 1 at concentrations of 5 μm and 1 μm (P/L 1:10 and 1:50).
Figure 5
Figure 5
Time course of normalized pyranine fluorescence after addition of: A,B) 5 μm to 50 nm 1 (P/L 1:10 to 1:1000) with A) proton influx from pH 6.4 to 7.4, B) proton efflux from pH 7.4 to 8.4, C) after addition of 1 μm (P/L 1:50) 11, 25, and 1, proton influx from pH 6.4 to 7.4. The vesicles were composed of POPC, total lipid concentration 50 μm containing 0.5 mm pyranine.

References

    1. Walsh T. R., Nat. Microbiol. 2018, 3, 854–855. - PubMed
    1. Zhang S., De Leon Rodriguez L. M., Leung I. K. H., Cook G. M., Harris P. W. R., Brimble M. A., Angew. Chem. Int. Ed. 2018, 57, 3631–3635; - PubMed
    2. Angew. Chem. 2018, 130, 3693–3697.
    1. Montenegro J., Ghadiri M. R., Granja J. R., Acc. Chem. Res. 2013, 46, 2955–2965. - PMC - PubMed
    1. Kaldas S. J., Yudin A. K., Chem. Eur. J. 2018, 24, 7074–7082. - PubMed
    1. Janek D., Zipperer A., Kulik A., Krismer B., Peschel A., PLoS Pathog. 2016, 12, e1005812. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources